Lloyd Damon, MD, Oncology, San Francisco, CA, UCSF Medical Center

LloydDamonMD

Oncology San Francisco, CA

Hematologic Oncology

Professor of Medicine, UCSF

Dr. Damon is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Damon's full profile

Already have an account?

Education & Training

  • UCSF
    UCSFResidency, Internal Medicine, 1982 - 1985
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 1982

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1983 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2006-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms
    Lloyd E. Damon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematolo...
    Lloyd E. Damon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • BiTEs, CAR T-cell Therapy Enhance ALL Armamentarium, but Questions Remain
    BiTEs, CAR T-cell Therapy Enhance ALL Armamentarium, but Questions RemainJanuary 22nd, 2020
  • OncLive® Announces the Latest State of the Science Summit™ on the Treatment of Hematologic Malignancies
    OncLive® Announces the Latest State of the Science Summit™ on the Treatment of Hematologic MalignanciesSeptember 19th, 2018

Hospital Affiliations